- In March 2026, Natural Cycles announced an integration with select Garmin smartwatches, enabling overnight skin temperature tracking to power its FDA-cleared birth control and fertility app across major markets including the US, EU, UK and others.
- This collaboration broadens Garmin’s wearable health capabilities into clinically regulated reproductive health, potentially deepening user engagement among women seeking non-hormonal birth control and fertility planning tools.
- We’ll explore how adding FDA-cleared reproductive health tracking via Natural Cycles could influence Garmin’s existing narrative around premium health services and wearables.
AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Garmin Investment Narrative Recap
To own Garmin, you need to believe its mix of premium devices and higher-margin services, like Garmin Connect+, can support earnings despite rising competition and costs. The Natural Cycles integration modestly reinforces the health and subscription story but does not meaningfully change near term catalysts or core risks such as margin pressure from higher R&D and SG&A or softness in Marine.
The launch of Garmin Connect+ remains the key near term catalyst, as it targets recurring, higher-margin revenue from AI-based health insights. In that context, the Natural Cycles partnership fits as another example of Garmin layering regulated health features on top of its hardware base, potentially helping justify its higher earnings multiple if user engagement and paid services adoption broaden over time.
Yet, while services like Garmin Connect+ and Natural Cycles integration could support margins, investors should still pay close attention to...
Read the full narrative on Garmin (it's free!)
Garmin's narrative projects $8.5 billion revenue and $1.8 billion earnings by 2028. This requires 7.9% yearly revenue growth and roughly a $0.2 billion earnings increase from $1.6 billion today.
Uncover how Garmin's forecasts yield a $260.25 fair value, a 10% upside to its current price.
Exploring Other Perspectives
In contrast, some of the lowest ranked analysts worry that even with integrations like Natural Cycles, rising competition and hardware commoditization could pressure the bearish case that already assumes only about US$9.3 billion of revenue and US$2.1 billion of earnings by 2029, so it is worth comparing these darker scenarios with more optimistic views before deciding what you believe.
Explore 4 other fair value estimates on Garmin - why the stock might be worth 21% less than the current price!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Garmin research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Garmin research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Garmin's overall financial health at a glance.
Looking For Alternative Opportunities?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com